Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

15articles mentioning drugs

78drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Pirfenidone ×

Pirfenidone

This drug is selected. Its supporting articles are shown below.

Pirfenidone15

Articles mentioning Pirfenidone

15 articles · page 2 of 2

P25 Impact of tiered service delivery model on antifibrotic adherence and mortality among patients with interstitial lung disease

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

97.2%

nintedanib pirfenidone idiopathic pulmonary fibrosis (IPF)interstitial lung disease (ILD)Aintree University Hospital PF-ILD progressive fibrotic ILD (PF-ILD)antifibrotic (AF) therapy

…one had a significantly higher discontinuation risk compared to nintedanib (HR 1.60, 95% CI 1.05–2.44, p=0.029).121 patients (44%) died be…

S91 Defining the antifibrotic mechanisms of treprostinil in pulmonary fibrosis

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

88.3%

Treprostinil nerandomilast nintedanib pirfenidone Idiopathic Pulmonary Fibrosis (IPF)pulmonary hypertension

…and hydroxyproline content levels in the PCLS model.Conclusions Treprostinil inhibits RhoA activation and this may be via PPARβδ activation.…

Differences in disease characteristics and outcomes as determined by biological sex in a large UK idiopathic pulmonary fibrosis population: analysis from the British Thoracic Society, Interstitial Lung Disease registry data

bmjresp · abstract · 2025-09-25 · 1 matching annotations

88.8%

nintedanib pirfenidone gastro-oesophageal reflux disease cardiovascular disease Diabetes major depressive illness idiopathic pulmonary fibrosis lung cancer antifibrotics

…baseline (pirfenidone FVC 50%–80% males 54.7% vs females 47.6%, nintedanib FVC 50%–80% males 47.0% vs females 41.5%, p<0.001), a larger pr…